AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36081312
Drug: 6-week tongue
RxNorm normalized name: BEEF TONGUE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week tongue elevation training program consisting of anterior tongue elevation strength and endurance tasks with the Iowa Oral Performance Instrument.
Trial: 33234910
Drug: Smartphone app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Smartphone app reminder for ASA adherence (81 mg twice daily for 35 days)
Trial: 34402328
Drug: Pegfilgrastim administration
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administration <20 hours after chemotherapy
Trial: 34402328
Drug: Pegfilgrastim administration
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administration ≥24 hours after chemotherapy
Trial: 34402328
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of pegfilgrastim administration (earlier or later than 20 hours)
Trial: 34402328
Drug: Overall outcomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall outcomes of pegfilgrastim administration
Trial: 32108322
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of plasma gel
Trial: 32108322
Drug: Combined plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined plasma gel and dermaroller
Trial: 32074767
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg daily for 3 days
Trial: 32074767
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix 0.25 mg subcutaneously daily for 3 days)
Trial: 32074767
Drug: Letrozole and
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole and GnRH antagonist
Trial: 36180610
Drug: Denosumab (subcutaneous)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab (subcutaneous) for osteoporosis, 5 years continuous treatment
Trial: 36180610
Drug: Denosumab (subcutaneous)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab (subcutaneous) for osteoporosis
Trial: 34561195
Drug: Beta-blockers (yes)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (yes)
Trial: 34561195
Drug: Beta-blockers (no)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (no)
Trial: 34561195
Drug: Short antiplatelet
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short antiplatelet therapy (1 month)
Trial: 34561195
Drug: Prolonged antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antiplatelet therapy (12 months)
Trial: 34678987
Drug: Low-dose neubotulinum
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose neubotulinum toxin A (Neu-BoNT-A)
Trial: 34678987
Drug: Low-dose abobotulinum
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose abobotulinum toxin A (Abo-BoNT-A)
Trial: 32109743
Drug: Total crystalloid
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total crystalloid volume (TCV) below 3 L
Trial: 32109743
Drug: Total crystalloid
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total crystalloid volume (TCV) above 6 L
Trial: 33843370
Drug: Tele-problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-problem-solving therapy (Tele-PST)
Trial: 33616641
Drug: Low-dose mycophenolate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mycophenolate mofetil
Trial: 36366886
Drug: Q-122 100
RxNorm normalized name: Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-122 100 mg, twice daily for 28 days
Trial: 36366886
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 28 days
Trial: 32598700
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (ET) with the addition of the prebiotic Zakofalk (inulin + butyrate)
Trial: 32598700
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (ET) with the addition of probiotics (lacto- and bifidobacteria)
Trial: 32598700
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (ET) without the addition of pre- or probiotics
Trial: 32809153
Drug: Immunotherapy (potential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (potential for use in PD)
Trial: 35360106
Drug: Probiotic dose
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic dose 2.5 × 10^9 CFU/day (n = 18)
Trial: 35360106
Drug: Probiotic dose
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic dose 1 × 10^10 CFU/day (n = 18)
Trial: 33850467
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment at outpatient clinic
Trial: 32055717
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (HF) - 58 Gy/40 fractions, twice daily
Trial: 32055717
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (CF) - 51 Gy/20 fractions, once daily
Trial: 32385851
Drug: Long-acting pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting pasireotide 10 or 30 mg every 28 days (minimum/maximum dose: 5/40 mg)
Trial: 35176206
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil 40 mg
Trial: 35176206
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil 80 mg
Trial: 35176206
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil (both doses)
Trial: 35809371
Drug: V590 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V590 (all dose levels)
Trial: 34472117
Drug: Vatinoxan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatinoxan (0.1 mg/kg)
Trial: 32861668
Drug: EX2 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX2 (5 times a week, twice daily, 50 sessions; n=286)
Trial: 32861668
Drug: EX1 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX1 (5 times a week, once daily, 25 sessions; n=272)
Trial: 33852251
Drug: CAL/BDP cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL/BDP cream
Trial: 35294415
Drug: Vonoprazan 20mg
RxNorm normalized name: VONOPRAZAN 20MG TAB
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan 20mg once-daily
Trial: 35294415
Drug: Lansoprazole 30mg
RxNorm normalized name: LANSOPRAZOLE 30MG CAP,SA
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30mg once-daily
Trial: 34085549
Drug: Intradermal mesotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal mesotherapy
Trial: 33276738
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment adherence
Trial: 33276738
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment completion
Trial: 33276738
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking after HCV treatment
Trial: 35588897
Drug: Olpasiran 10
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 10 mg q12 weeks
Trial: 35588897
Drug: Olpasiran 75
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 75 mg q12 weeks
Trial: 35588897
Drug: Olpasiran 225
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 225 mg q12 weeks
Trial: 35588897
Drug: Olpasiran 225
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran 225 mg q24 weeks
Trial: 33416226
Drug: Sequential Splints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Splints Method
Trial: 36227234
Drug: Rest Redistribution
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest Redistribution with Heavier Loads (RR + L): 4 sets of (2 × 5) repetitions with 90-second interset rest and 30-second intraset rest using 75% BS 1RM
Trial: 33785496
Drug: Physiotherapist-led exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-led exercise therapy
Trial: 32065775
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering medication
Trial: 32065775
Drug: Lipid-lowering medications
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering medications
Trial: 32065775
Drug: Any CVD
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any CVD prevention medication
Trial: 32065775
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering medication use in high CVD risk
Trial: 32350058
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (antiplatelet medication such as aspirin or anticoagulation)
Trial: 32042286
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 50 µg once daily
Trial: 34763937
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg daily until progression or treatment discontinuation
Trial: 34494113
Drug: BEP supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP supplement
Trial: 34494113
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily iron‐folic acid tablet)
Trial: 33955348
Drug: Almond consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond consumption (1.5 oz daily with breakfast and as an afternoon snack)
Trial: 32975829
Drug: Portable gluten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portable gluten sensor (low, medium, and high numbers of single-use capsules)
Trial: 36203046
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (b.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) ophthalmic gel
Trial: 36203046
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily (q.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) eye drops
Trial: 34278611
Drug: ZOL 5-mg
RxNorm normalized name: Zol
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZOL 5-mg infusion
Trial: 35799973
Drug: Internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive-behavioral therapy
Trial: 33704353
Drug: Ablative radiation
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative radiation therapy (A‐RT) at 98 Gy biologically effective dose
Trial: 33704353
Drug: Ablative radiation
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative radiation therapy (A‐RT)
Trial: 36862472
Drug: Cognitive-behavioral couple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral couple therapy (CBCT)
Trial: 36451139
Drug: EMDR (Eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR (Eye Movement Desensitization and Reprocessing) therapy, 3 to 5 sessions
Trial: 35694079
Drug: Inhalation groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation groups (Desflurane, Propofol, Sevoflurane)
Trial: 32585039
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (7.5 mg/kg body weight)
Trial: 32250530
Drug: Lyo avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyo avexitide (exendin 9-39) at ascending doses, administered SC twice daily for 3 days
Trial: 32250530
Drug: Liq avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liq avexitide (exendin 9-39) at a fixed dose of 30 mg, administered SC twice daily for 3 days
Trial: 35039301
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate ointment (5 times a day)
Trial: 35039301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual oral hygiene guidance only)
Trial: 35765222
Drug: RT001 (2.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT001 (2.88 g/day, increased to 8.64 g/day as tolerated)
Trial: 35765222
Drug: RT001 (5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT001 (5.6 ± 1.6 g/day; dose range, 1.92 to 8.64 g/day)
Trial: 34389633
Drug: GSK2982772 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 60 mg three times daily for 42 days
Trial: 33357510
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin (AUC5 or AUC6) and intravenous paclitaxel (175 mg/m2) on day 1 of every 21‐day cycle (control group)
Trial: 33357510
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 2)
Trial: 33357510
Drug: Intravenous dose‐fractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose‐fractionated carboplatin (AUC2) and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 3)
Trial: 32474130
Drug: 5-session telephone-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST)
Trial: 32474130
Drug: 5-session telephone-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-session telephone-administered coping effectiveness training (teleCET)
Trial: 32186013
Drug: Jiawei Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiawei Xiaoyao (JWXY) capsules
Trial: 35129242
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n = 59)
Trial: 35129242
Drug: HIV clinic‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV clinic‐based extended‐release naltrexone (XR‐NTX) among those initiating medication
Trial: 35129242
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) among those initiating medication
Trial: 34486272
Drug: Lactoginal vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoginal vaginal probiotic after standard antibacterial therapy
Trial: 32273244
Drug: Sleep improvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep improvement intervention (3 weekly sessions lasting 90 to 120 minutes)
Trial: 32847917
Drug: Xueshuantong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong injection (lyophilised) (XST)
Trial: 32847917
Drug: 1/20th dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/20th dose of Xueshuantong injection (lyophilised) (Control)
Trial: 39755573
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (control group)
Trial: 32444250
Drug: Azathioprine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2.5 mg/kg/day with oral curcumin 3 g/day
Trial: 34432204
Drug: Kangfuyan Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuyan Capsules (4 capsules, 3 times daily for 12 weeks)
Trial: 34432204
Drug: Gongyanping Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gongyanping Capsules (control group, 4 capsules, 3 times daily for 12 weeks)
Trial: 33966118
Drug: metreleptin treatment
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metreleptin treatment
Trial: 32581041
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and docetaxel (first-line treatment)
Trial: 36154603
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg tablet 90 minutes before surgery
Trial: 36154603
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 µg tablet 90 minutes before surgery
Trial: 32982212
Drug: Ensifentrine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 0.75 to 6mg twice daily
Trial: 33120137
Drug: Cognitive-behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural group therapy (N = 67)
Trial: 33120137
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction group therapy (N = 58)
Trial: 36327169
Drug: Low-dose alfaxalone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alfaxalone (LDA) 2 mg/kg
Trial: 36327169
Drug: High-dose alfaxalone
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alfaxalone (HDA) 5 mg/kg
Trial: 35621299
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (20 mg from day 1 of the menstrual cycle till trigger day)
Trial: 35621299
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone antagonist (Cetrorelix 0.25 mg s/c from the day leading follicle reached 14 mm until trigger day)
Trial: 35621299
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone antagonist
Trial: 35222900
Drug: Conventional stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional stroke treatment and nursing
Trial: 34154628
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment group (balloon group, n = 38)
Trial: 34154628
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) treatment group (stent group, n = 42)
Trial: 34154628
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment group (balloon group)
Trial: 34154628
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) treatment group (stent group)
Trial: 35069956
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 15 mg (Group R)
Trial: 35069956
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 15 mg with intrathecal fentanyl 20 μg (Group RF)